DIRS.INFO The most relevant business & tech news

☆ Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
▼ + stars: | 2024-09-16 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +9 min

watch nowDrugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough. That can allow the treatment to deliver radiation to cancer cells and spare the rest of the body from the level of damage that comes with many cancer drugs. For Pluvicto, patients come in once every six weeks for up to six treatments. One opportunity Bristol Myers Squibb sees is combining radiopharmaceuticals with existing cancer drugs like immunotherapy, said Robert Plenge, Bristol's chief research officer. But she thinks the technology will become an important part of cancer drugs in the next decade.

Persons: Eli Lilly, They've, Michael Schmidt, Schmidt, Franco Origlia, Jacob Van Naarden, Eli Lilly's, Lilly, Biopharma, Van Naarden, Radiopharmaceuticals, Bristol Myers, Ben Hickey, RayzeBio, Hickey, Victor Bulto, Bulto, Timothy Korytko, Ronald Coy, Sharon, Ronald Coy Ronald Coy, Coy, who's, Coy hasn't, she's, we've, Eli Lilly's Van Naarden, Bristol Myers Squibb, Robert Plenge, Susan Galbraith, Galbraith Organizations: Bristol Myers Squibb, AstraZeneca, Guggenheim Securities, Novartis, NSA, Pharmaceutical, Bassett Healthcare Network, Bristol, Fusion Pharmaceuticals, Guggenheim Locations: Aedea Rome, Italy, radiopharmaceuticals, Swiss, FactSet, Bristol, Indiana, U.S, New York, Bassett

6:59 a.m.: Citi raises AT & T price target A wave of improving outlook for telecommunications could benefit shares of AT & T , according to Citi. The firm upgraded the telecommunications company to neutral from sell and left its $350 per share price target unchanged. "Although our 2028 EPS is still c16% ahead of consensus, we now see less scope for earnings outperformance 2024/2025," the analyst added. The firm upgraded the home furnishings stock to buy from hold and increased its price target to $156 per share to $148. His price target of $105, down from $122, implies upside of just 8.7% from Tuesday's close.

Persons: Goldman Sachs, Morgan Stanley, Jefferies, Michael Rollins, Rollins, — Brian Evans, Graham Parry, Parry, Sonoma Jefferies, William, Jonathan Matuszewski, Matuszewski, Brian Evans, Goldman Sachs downgrades Morgan Stanley, Richard Ramsden, Ramsden, Fred Imbert Organizations: CNBC, Williams, Citi, AT, JV, Apple, Communications Citi, Communications, Charter Communications, Bank of America downgrades Novartis Bank of America, Novartis, William, Elm, Brands, WSM, Goldman Sachs downgrades Morgan Stanley Investors Locations: U.S, Sonoma, Swiss, William, Tuesday's

☆ Stocks making the biggest moves midday: GameStop, Viking Therapeutics, Trump Media and more
▼ + stars: | 2024-09-11 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Trump Media & Technology — The stock fell more than 13% following Tuesday's debate between majority shareholder former President Donald Trump and Democratic Vice President Kamala Harris. Novartis — U.S.-listed shares of the Swiss pharma company slipped nearly 2% on the heels of Bank of America's downgrade to hold from buy. Crypto stocks — Crypto stocks were dragged downward after the price of bitcoin fell slightly overnight, as crypto traders considered central bank policy in Japan . Morgan Stanley — The bank stock lost 1% following a downgrade at Goldman Sachs to neutral from buy. Solar stocks — Solar stocks rose as a group after Vice President Kamala Harris's performance at Tuesday's debate raised confidence in a Democratic victory at the U.S. presidential election.

Persons: Donald Trump, Kamala Harris, Rentokil, it's, bitcoin, Morgan Stanley, Goldman Sachs, Goldman, Morgan, Warren Buffett's Berkshire Hathaway, Kamala Harris's, — CNBC's Sean Conlon, Michelle Fox, Alex Harring, Yun Li, Sarah Min, Samantha Subin Organizations: Trump Media & Technology, Democratic, Trump Media, Nasdaq, GameStop, Novartis — U.S, Swiss pharma, of, Therapeutics, JPMorgan, Viking Therapeutics, Goldman, Bank of America, U.S, Clean Energy, SolarEdge Technology, Sunnova Energy Locations: North America, Japan

☆ Stocks making the biggest moves premarket: Trump Media, GameStop, Dave & Buster's and more
▼ + stars: | 2024-09-11 | by ( Sean Conlon | ) www.cnbc.com time to read: +2 min

Trump Media & Technology – Shares slid more than 11% in the wake of the debate between Republican nominee Donald Trump and Democratic Vice President Kamala Harris . Dave & Buster's – The entertainment stock popped more than 13% after topping earnings estimates for the recent quarter by 15 cents a share. GameStop – The video game retailer's shares plunged more than 10% in premarket trading after the company reported a steep decline in sales. GameStop also announced an "at-the-market" stock offering of up to 20 million shares. Morgan Stanley – Shares of the major bank were down more than 1% after Goldman Sachs downgraded the stock to neutral from buy.

Persons: Donald Trump, Kamala Harris, Rentokil, Rollins, Dave, Buster's, Jefferies, Stocks, Coinbase, MicroStrategy, MARA, Morgan Stanley –, Goldman Sachs, Goldman, Morgan Stanley, —, Alex Harring, Samantha Subin, Jesse Pound, Yun Li, Sarah Min, Tanaya Macheel, Michelle Fox Organizations: Trump Media & Technology, Republican, Democratic, Trump Media, GameStop, Williams, Sonoma, Jefferies, Novartis – U.S, Bank of America, Novartis, Viking Therapeutics, JPMorgan, MARA Holdings Locations: North America, Swiss, Japan

☆ Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data
▼ + stars: | 2024-07-29 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. However, in an FT interview published earlier Monday, CEO Thomas Schinecker indicated that the firm's first obesity drug could come to market "significantly faster than people are expecting," potentially by 2028. Both CT-388 and CT-996 were acquired as part of Roche's purchase of U.S. biotech company Carmot Therapeutics, which completed in January. The promising results could see Roche emerge as a potential rival to obesity drug pioneers Novo Nordisk and Eli Lilly. Schinecker told CNBC last week that he expects the company to eventually offer a suite of obesity medications.

Persons: Roche, Nordisk's Wegovy, Eli Lilly, Thomas Schinecker, Teresa Graham, Roche's, Schinecker Organizations: Nordisk's, CNBC, Roche Pharmaceuticals, Carmot Therapeutics, Novo Nordisk Locations: U.S

☆ Novo Nordisk's Wegovy wins EU backing for reducing heart risks
▼ + stars: | 2024-07-26 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand the medicine's use to include reducing the rise of serious heart events in overweight and obese adults. "The SELECT data demonstrated that in addition to helping people manage their weight, Wegovy has the potential to protect lives by reducing the risks of major adverse cardiovascular events." Novo Nordisk said it expects to implement the label update within a month. The company's CEO Thomas Schinecker welcomed positive early stage trial results from the firm's two weight loss drug candidates as showing "best in disease potential."

Persons: Wegovy, —, Martin Holst Lange, Roche, Thomas Schinecker Organizations: Novo Nordisk, Novo, European Medical Agency, U.S . Food, Drug Administration Locations: Danish, U.S, Swiss

☆ Wegovy rival to be part of a suite of weight loss drugs, Roche CEO says following positive trial results
▼ + stars: | 2024-07-25 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Roche said Thursday that its Wegovy rival weight loss drugs will be part of a suite of medicines aimed at combatting the effects of obesity. CEO Thomas Schinecker welcomed positive early stage trial results from the firm's two weight loss drug candidates as showing "best in disease potential." "We do believe we have two next generation GLP-1/GIPs that have a best in disease potential," he said of the obesity drugs. GLP-1s, or glucagon-like peptide 1 agonists, are a group of drugs used to treat diabetes and obesity. They form the basis of weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Persons: Roche, Thomas Schinecker, Schinecker, CNBC's, Nordisk's Wegovy, Eli Lilly's Zepbound Organizations: Nordisk's

☆ How CrowdStrike's stumble could impact our cybersecurity stock Palo Alto
▼ + stars: | 2024-07-19 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Shares of Club holding Palo Alto Networks rose more than 1% Friday after an update from its cybersecurity rival CrowdStrike caused a widespread IT outage across the globe. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, CrowdStrike, Nikesh Arora, Jeff Marks, Jeff, Eli Lilly, Jim, Lilly, Roche, Eli Lilly's, Jim Cramer's Organizations: CNBC, Nasdaq, Dow Jones, Palo Alto Networks, Palo Alto, Novo Nordisk Locations: Danish

☆ We're upgrading Eli Lilly after an overdone sell-off on competition fears
▼ + stars: | 2024-07-18 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Upgrading Lilly: Shares of Eli Lilly have been hit hard since making a new closing high on Monday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, Roche, there's, Lilly, we'll, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Energy, Nvidia, Lilly, Novo Nordisk, Netflix, PPG Industries, American, Halliburton, Jim Cramer's Charitable Locations: Swiss

☆ Eli Lilly falls on a rival's obesity study — plus, we're removing 3 stocks from our watchlist
▼ + stars: | 2024-05-16 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Eli Lilly dips: Shares of Eli Lilly are sitting out the rally on news that Swiss pharmaceutical firm Roche 's experimental obesity drug demonstrated promise in a Phase 1 study. "Doug McMillon, the CEO of Walmart, made the point repeatedly that the company's success this quarter came from lower prices," Jim Cramer said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, Roche, It's, inflect, We're, Doug McMillon, Estee Lauder, Jim, Jim Cramer's Organizations: CNBC, Viking Therapeutics, Club, Deere, Walgreens Boots, Walmart, Costco, Materials, Jim Cramer's Charitable Locations: Swiss, Amgen, China

☆ 'Ozempic face' could create a huge market for fillers. One newly-public company wants to cash in.
▼ + stars: | 2024-04-25 | by ( Geoff Weiss | Julia Pugachevsky | ) www.businessinsider.com time to read: +1 min

Its CEO told Bloomberg that weight-loss drugs could boost its fillers business. Ozempic face is a result of aging and rapid weight loss, one cosmetic dermatologist said. NEW LOOK Sign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. AdvertisementThe CEO of Swiss pharmaceutical giant Galderma thinks the popularity of weight-loss drugs like Ozempic could boost its facial fillers business. That's because Ozempic can result in a sunken-in look in some patients' faces, Galderma CEO Flemming Ornskov told Bloomberg — an effect he said fillers can help counteract.

Persons: —, Flemming Ornskov, Flemming Organizations: Swiss pharma, Bloomberg, Service, Business Locations: Swiss

One strategist, however is looking keenly at European equities, and notes that "Europe isn't a boring market." "You would hope that will translate through to the stock market in terms of company earnings growth in Europe. "While you might see some kind of short-term downturn, in the longer-term the picture is very positive for the sector," Field added. He sees value in payments, which he described as "one of the most undervalued parts of European financial services." The sector has trailed market performance, with valuations looking "interesting" over the last 12 months, Morningstar noted in its recent report.

Persons: Michael Field, Field, Morningstar Organizations: CNBC Pro, European Central Bank, Consumer, Swatch Group, Financial, Morningstar, ING Bank, Group, Health, Novo Nordisk Locations: U.S, Europe, Netherlands, British, Swiss

☆ Swiss pharma giant Roche's first-quarter sales edge higher as its emerges from post-Covid-19 slump
▼ + stars: | 2024-04-24 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Swiss pharmaceutical company Roche on Wednesday reported a modest uptick in first-quarter sales, even as waning demand for its Covid-19 products continued to weigh on the company. Sales were up 2% at constant exchange rates, led by stronger demand for Roche's newer medicines and diagnostics, the company said. Excluding Covid-19 products, sales were up 7%. But sales tightened when reported in the company's local currency, down 6% off the back of a strong Swiss franc. Roche CEO Thomas Schinecker on Wednesday confirmed the company's 2024 outlook, saying it was largely out of the woods following a post-Covid-19 slump.

Persons: Roche, Thomas Schinecker, Schinecker Organizations: Roche, AG, Wednesday, Reuters Locations: Basel, Switzerland, Swiss

☆ Roche enters obesity market with Carmot takeover but drugs may not be available until 2030
▼ + stars: | 2023-12-04 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

BRAZIL - 2021/11/26: In this photo illustration a F. HoffmannLa Roche AG logo is seen on a screen and a hand holding a pill. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images)Swiss pharmaceuticals giant Roche is set to acquire anti obesity drug developer Carmot Therapeutics, becoming the latest company to attempt to unseat Novo Nordisk and Eli Lilly's dominance within the global weight-loss drugs market. The U.S. takeover target's early-stage technology could help crack highly prized oral obesity treatments, Roche Pharmaceuticals CEO Teresa Graham said Monday, but it may be several years before the drugs are widely available. The deal will provide Roche access to Carmot's current research and development portfolio, including all clinical and preclinical assets. Shares of the Swiss company, which have been in the doldrums this year, were up 2.25% following the news of the acquisition.

Persons: HoffmannLa Roche, Rafael Henrique, Roche, Eli Lilly's, Teresa Graham, we'll, Graham, CNBC's Julianna Tatelbaum, Eli Lilly's Mounjaro Organizations: Getty Images, Carmot Therapeutics, Novo Nordisk, U.S, Roche Pharmaceuticals, Roche Locations: BRAZIL, Swiss, California

☆ Roche’s late obesity punt offers wider market cure
▼ + stars: | 2023-12-04 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Arnd Wiegmann Acquire Licensing RightsLONDON, Dec 4 (Reuters Breakingviews) - Roche’s (ROG.S) foray into the prospective $100 billion obesity market can bring wider benefits. On Monday, the $224 billion Swiss pharma group said it had agreed to take over weight-loss drug developer Carmot Therapeutics for $2.7 billion. Market leader Novo Nordisk (NOVOb.CO) is already selling obesity drugs in the U.S. and parts of Europe. Still, Schinecker’s obesity bet could turn successful if it ends up undercutting obesity pioneers on prices. With over 1 billion people globally classed as seriously overweight, other drugmakers will follow Roche on the obesity bandwagon.

Persons: drugmaker Roche, Arnd, Eli Lilly’s, Thomas Schinecker, Eli Lilly, Eccogene, Roche, Aimee Donnellan, Neiman Marcus, Lisa Jucca, Oliver Taslic Organizations: REUTERS, Reuters, Swiss pharma, Carmot Therapeutics, Novo Nordisk, U.S . Food, Drug Administration, AstraZeneca, Novo, X, Saks, Thomson Locations: Basel, Switzerland, U.S, Europe, Hong Kong

☆ Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion
▼ + stars: | 2023-10-23 | by ( Adrià Calatayud | ) www.wsj.com time to read: 1 min

Roche’s deal is the latest example of a big pharma company turning to the deal table to bolster its pipeline of autoimmune drugs. Photo: Philipp Schmidli/Bloomberg NewsRoche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences , a company started by Republican presidential candidate Vivek Ramaswamy , and Pfizer in a deal worth more than $7 billion. The Swiss pharmaceutical giant said Monday it would pay $7.1 billion upfront for Telavant Holdings, and make a near-term milestone payment of $150 million. Roche said the deal gives it rights to commercialize Telavant’s RVT-3101 drug candidate, which has shown promise for inflammatory-bowel disease and could have potential in other indications, in the U.S. and Japan.

Persons: Philipp Schmidli, Vivek Ramaswamy, Roche Organizations: pharma, Bloomberg, Roche Holding, Roivant Sciences, Republican, Pfizer, Telavant Holdings, Telavant’s Locations: Swiss, U.S, Japan

☆ Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings
▼ + stars: | 2023-10-23 | by ( Hannah Ward-Glenton | ) www.cnbc.com time to read: +1 min

Swiss health care company Roche on Monday announced it would acquire Telavant Holdings in a $7.1 billion transaction. Telavant produces drugs for people suffering from inflammatory and fibrotic diseases and is in the process of developing a "promising new therapy" for patients with Crohn's disease, Roche said in a press release. "We are eager to develop this antibody further and bring it to market and patients in the US and Japan as soon as possible." Telavant is currently owned by Pfizer and Roivant Sciences. In the Monday announcement, Roche also said it would obtain an option to collaborate with Pfizer on a new inflammatory bowel disease drug.

Persons: Roche, — Roche, Teresa Graham, Telavant Organizations: Monday, Telavant Holdings, Roche Pharmaceuticals, CNBC, Pfizer, Roivant Sciences Locations: Japan

☆ Roche's $7 bln deal is pricey and partial cure
▼ + stars: | 2023-10-23 | by ( ) www.reuters.com time to read: +2 min

Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/Illustration Acquire Licensing RightsNEW YORK, Oct 23 (Reuters Breakingviews) - Roche (ROG.S) has taken a small step towards curing its drug pipeline problem. JPMorgan analysts estimate that the drug’s U.S. sales could peak at 2.4 billion Swiss francs ($2.7 billion), but will take until 2037 to get there, assuming a 2028 launch. Analysts expect Roche’s pharmaceutical division to generate revenue of almost 45 billion Swiss francs this year, according to estimates compiled by LSEG. With expected free cash flow of around 16 billion Swiss francs this year and next, Roche can afford to buy a little more diversification.

Persons: Roche, Dado Ruvic, Thomas Schinecker, Peter Thal Larsen, Jean, Pierre Mustier, Atos, Jonathan Guilford, Aditya Sriwatsav Organizations: REUTERS, Reuters, Pfizer, U.S, New, JPMorgan, Merck, Prometheus Biosciences, Analysts, LSEG, X, News Corp, Thomson Locations: Swiss, U.S

☆ Novartis' Sandoz valued at $11.2 bln in market debut
▼ + stars: | 2023-10-04 | by ( ) www.reuters.com time to read: +1 min

A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021. REUTERS/Brian Snyder/File Photo Acquire Licensing RightsOct 4 (Reuters) - Sandoz (SDZ.S) made its market debut with a lower-than-expected valuation of 10.3 billion Swiss francs ($11.2 billion) on Wednesday, after the generic and biosimilar drugmaker was spun off from Swiss pharmaceutical company Novartis (NOVN.S). Deutsche Bank had said Sandoz, which accounted for 11% of Novartis' group operating profit in 2022, would likely be valued at $11-$13 billion, while brokerage Berenberg had forecast $17-$26 billion. The shares, which opened at 24 Swiss francs, became members of the Swiss Performance Index and the Swiss Leader Index, among other stock market gauges, and American depositary receipts also started trading on Wednesday. Novartis shareholders received one Sandoz share for every five Novartis shares they held as part of the transaction.

Persons: Brian Snyder, drugmaker, Sandoz, Berenberg, Vas Narasimhan, Ludwig Burger, Tristan Veyet, Clarence Fernandez, Mark Potter Organizations: Novartis, Research, REUTERS, Sandoz, Analysts, Deutsche Bank, Swiss, Thomson Locations: Cambridge , Massachusetts, U.S, Swiss, generics

☆ Pakistan probes distributors of Roche cancer drug after patients go blind
▼ + stars: | 2023-09-25 | by ( Mubasher Bukhari | ) www.reuters.com time to read: +3 min

REUTERS/Arnd Wiegmann/File Photo Acquire Licensing RightsLAHORE, Pakistan, Sept 25 (Reuters) - Pakistan said on Monday it was investigating two local distributors of Swiss pharmaceutical company Roche's (ROG.S) Avastin cancer drug after 12 diabetic patients injected with the drug went blind. The Drug Regulatory Authority of Pakistan (DRAP) said the health authorities in Punjab, the most populous province, had launched the investigation into local use of the drug Avastin, which is licensed for use in Pakistan. On its website, Roche said Avastin was approved in more than 130 countries, including the United States, to treat several types of cancer. Cancer drug Avastin, when used at much lower doses, is similar to eye drug Lucentis and is used in many countries as a low-cost option to treat certain blindness-causing conditions. In its statement, Roche said: "Avastin is not approved for any use in the eye.

Persons: drugmaker Roche, Arnd, Javed Akram, Akram, Roche, Avastin, Alam, Mubasher Bukhari, Ariba Shahid, Ludwig Burger, Miral Fahmy, Alex Richardson Organizations: REUTERS, Rights, Drug Regulatory Authority of Pakistan, Reuters, U.S ., Thomson Locations: Basel, Switzerland, Rights LAHORE, Pakistan, Swiss, Punjab, United States, counterfeits, Avastin, Lahore, Karachi, Frankfurt

☆ 'A comeback in the making': UBS expects these under-the-radar European stocks to soar
▼ + stars: | 2023-09-08 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +3 min

UBS has named a raft of European small and midcap stocks it says are staging a "comeback in the making" this year. Smaller European stocks returned 0.5% in July and August, outperforming the 1.7% contraction logged by large caps in the same period, the Swiss investment bank noted. On average, stocks on UBS' list of small and mid-cap stocks were up 6.6% year-to-date, beating the MSCI European Smallcap Index by 1.2 percentage points, according to the bank. Stock picks Italian cement and ready-mix company Buzzi is among UBS' top picks, given its year-to-date performance of 53.4%. New on the radar UBS' list has also undergone a refresh to include three new stocks: Galenica , SIG Group and Talgo.

Persons: Knorr, Hugo Boss, Galenica Organizations: UBS, Stock, Bremse, SIG Group, Swiss pharma, SIG Locations: Swiss

☆ Novartis raises 2023 forecast, maps out Sandoz spin-off
▼ + stars: | 2023-07-18 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

Companies Novartis AG FollowSandoz GmbH FollowFRANKFURT, July 18 (Reuters) - Novartis (NOVN.S) on Tuesday raised its full-year earnings forecast on strong drug sales and mapped out the planned spin-off and stock market debut of its generic medicines division Sandoz for early October. The Swiss drugmaker said in a statement it expected group core operating income to grow by a "low double-digit" percentage in 2023, up from high single-digit growth previously projected. Novartis shareholders will vote on the proposed Sandoz spin-off and complete separation at an extraordinary general meeting on Sept. 15. Gains were driven by better-than-expected sales of heart failure drug Entresto, up 37% in local currencies at $1.52 billion. Kesimpta, a new once-a-month injection against multiple sclerosis, also beat expectations with quarterly revenues more than doubling to $489 million.

Persons: Swiss drugmaker, Sandoz, Harry Kirsch ., Kirsch, Ludwig Burger, Rachel More, Sharon Singleton Organizations: Novartis, Sandoz, FRANKFURT, SIX Swiss Exchange, Swiss pharma, Thomson Locations: Swiss, United States, New Jersey

☆ Stocks making the biggest moves midday: Morgan Stanley, Bank of America, Charles Schwab and more
▼ + stars: | 2023-07-18 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

Morgan Stanley — Shares of the James Gorman-led bank jumped more than 6% after the firm posted second-quarter earnings and revenue that topped analysts' expectations. Bank of America – Bank of America shares rose nearly 4% after the company reported second-quarter financial results. Bank of New York Mellon — Shares rose more than 4% after Bank of New York Mellon reported second-quarter revenue and profit that beat Wall Street's expectations. PNC Financial — Shares gained 2.6% after PNC Financial reported second-quarter earnings that topped Wall Street's earnings expectations but came in slightly short on revenue. The Swiss pharmaceutical firm reported second-quarter earnings that topped estimates, according to StreetAccount.

Persons: Charles Schwab, Morgan Stanley —, James Gorman, Morgan Stanley's, Refinitiv, PacWest, Bernstein, UnitedHealth, Pinterest, intraday, Masimo preannounced, Stifel, Lockheed Martin, Macheel, Sarah Min, Yun Li, Alex Harring, Michelle Fox Organizations: Bank of America – Bank of America, Regional Banking, Western Alliance, FB Financial, Verizon, AT, Bank of New York Mellon, PNC, PNC Financial, Novartis — U.S, Novartis, Sandoz, Masimo, Lockheed Locations: San Francisco , California, Swiss, FactSet

☆ Novartis buyback offers partial cure for M&A risk
▼ + stars: | 2023-07-18 | by ( ) www.reuters.com time to read: +2 min

LONDON, July 18 (Reuters Breakingviews) - Novartis’s (NOVN.S) bumper buyback will offer a little relief to investors. Many had been waiting to see what the $225 billion Swiss pharma giant would do with an extra $20 billion burning a hole in its pocket after Roche(ROG.S) bought back its stake in 2021. It needs new drugs to replenish its pipeline and boost an ailing share price, which has still not recovered since the pandemic. But on Tuesday, CEO Vasant Narasimhan said he will launch a $15 billion buyback programme. The Swiss drugmaker’s $15.4 billion of net debt is less than 1 times its forecast 2023 EBITDA, according to Refinitiv.

Persons: Roche, Vasant Narasimhan, can’t, Aimee Donnellan, Xavier Niel’s, Neil Unmack, Streisand Neto Organizations: Reuters, Swiss pharma, Alcon, Madrigal Pharmaceuticals, Novartis, Twitter, Xavier Niel’s GAM, Commonwealth Games, Thomson Locations: Swiss

☆ Bausch + Lomb to buy Novartis dry-eye drug for $1.75 bln
▼ + stars: | 2023-06-30 | by ( ) www.reuters.com time to read: 1 min

June 30 (Reuters) - Bausch + Lomb Corp (BLCO.TO) will purchase a dry-eye drug from Swiss pharma company Novartis (NOVN.S) for $1.75 billion, the companies said on Friday, as the contact lens maker seeks to capitalise on a growing market for the disease's treatment. Acquisition of the drug, Xiidra, will mark the first big deal by CEO Brent Saunders since he returned to the company in March. Sales of the anti-inflammation eye drop Xiidra, mainly from the U.S. market, were $487 million last year, up 4%. The deal will also include potential milestone payments worth up to $750 million. Reporting by Leroy Leo in Bengaluru and Ludwig Burger in Frankfurt; Editing by Anil D'Silva and Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

Persons: Brent Saunders, Leroy Leo, Ludwig Burger, Anil D'Silva, Vinay Dwivedi Organizations: Lomb, Swiss pharma, Novartis, Thomson Locations: U.S, Bengaluru, Frankfurt

Search resuls for: "Swiss pharma"

25 mentions found